Kite And Humanigen Announce Clinical Collaboration To Evaluate Investigational Combination Of Yescarta® (Axicabtagene Ciloleucel) With Lenzilumab In Relapsed/Refractory Diffuse Large B-Cell Lympho
Pearl Cohen is an international law firm with offices in Israel, the United States, and the United Kingdom. Our strength is derived from decades of legal experience and an intimate knowledge of the cutting edge technological, legal, and transactional issues facing our clients in local and cross border matters. This combination of experience and knowledge allows us to provide sound and innovative advice to clients worldwide.
Kite, a Gilead Company (GILD) and Humanigen, Inc., (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab,
Israel
Kite, a Gilead Company (GILD) and Humanigen, Inc., (HGEN)
announced today the formation of a clinical collaboration to
conduct a Phase 1/2 study of lenzilumab, an investigational
anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene
ciloleucel) in patients with relapsed or refractory diffuse large
B-cell lymphoma (DLBCL). The objective of this study is to
determine the effect of lenzilumab on the safety of Yescarta. Kite
will act as the sponsor of this study and will be responsible for
its conduct.
Mark Cohen, Senior Partner and Chair of the
Life Science Practice Group represents Humanigen, Inc. in its
intellectual property and commercial transactional matters.
Contributor
Pearl Cohen is an international law firm with offices in Israel, the United States, and the United Kingdom. Our strength is derived from decades of legal experience and an intimate knowledge of the cutting edge technological, legal, and transactional issues facing our clients in local and cross border matters. This combination of experience and knowledge allows us to provide sound and innovative advice to clients worldwide.
